
Israeli multinational Teva Pharmaceutical has decided to discontinue the development of laquinimod. As such, all rights for the orally administered …
Teva and Active Biotech’s oral MS drug laquinimod has failed to meet its primary endpoint in a phase III trial. …
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care

